STAGE IV PROSTATE CANCER
Clinical trials for STAGE IV PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new STAGE IV PROSTATE CANCER trials appear
Sign up with your email to follow new studies for STAGE IV PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to slow bone metastases in tough prostate cancer
Disease control OngoingThis study looks at whether adding a radiation drug (radium-223) to standard hormone therapy (enzalutamide) can better control prostate cancer that has spread to bone. About 30 men with castration-resistant prostate cancer will be randomly assigned to get enzalutamide alone or wi…
Matched conditions: STAGE IV PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 17, 2026 05:36 UTC
-
New Two-Punch strategy takes on tough prostate cancer
Disease control OngoingThis study tests a two-step treatment plan for men with high-risk prostate cancer that has spread. First, patients receive hormone therapy plus a newer drug, followed by chemotherapy. The goal is to improve survival by attacking the cancer in a way that makes it harder for it to …
Matched conditions: STAGE IV PROSTATE CANCER
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 17, 2026 05:30 UTC
-
Promising combo tackles tough prostate cancer
Disease control OngoingThis study tests a three-part treatment for men with intermediate or high-risk prostate cancer: a drug called enzalutamide, radiation therapy, and hormone therapy. The goal is to see how safe the combination is and how well it controls the cancer. About 25 men will take part, and…
Matched conditions: STAGE IV PROSTATE CANCER
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for Hard-to-Treat prostate cancer: targeted drug combo shows promise
Disease control OngoingThis study tests three treatment options for men with advanced prostate cancer that no longer responds to hormone therapy and has specific DNA repair defects. Participants receive either abiraterone (a hormone blocker), olaparib (a targeted drug), or both together. The goal is to…
Matched conditions: STAGE IV PROSTATE CANCER
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Smarter hormone therapy aims to control advanced prostate cancer with fewer side effects
Disease control OngoingThis study tests a new way of giving hormone therapy for stage IV prostate cancer that has not yet stopped responding to hormones. Instead of continuous treatment, the therapy is given in cycles based on PSA levels. The goal is to keep the cancer under control while reducing side…
Matched conditions: STAGE IV PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Prostate cancer drugs may cloud your mind: new study investigates
Knowledge-focused OngoingThis study looks at how certain hormone therapies for advanced prostate cancer might affect thinking skills like memory and attention. About 100 men who are already on these treatments will take thinking tests and have brain scans to see if there are changes. The goal is to under…
Matched conditions: STAGE IV PROSTATE CANCER
Phase: PHASE4 • Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated May 17, 2026 05:32 UTC